Lumos Pharma, Inc. (LUMO) |
| 4.34 0 (0%) 12-11 16:00 |
| Open: | 4.33 |
| High: | 4.34 |
| Low: | 4.33 |
| Volume: | 390,873 |
| Market Cap: | 38(M) |
| PE Ratio: | -1.01 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 4.5756 |
| 52w Low: | 1.3701 |
Lumos Pharma, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to advancing and commercializing medical treatments for rare conditions. Their principal therapeutic compound, LUM-201, an orally administered growth hormone secretagogue called ibutamoren, is currently undergoing Phase 2 clinical evaluation. This drug candidate is being investigated for its potential in treating pediatric growth hormone deficiency and various other uncommon endocrine conditions. The company's operations are based in Austin, Texas.
Financials
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Company news
Wed, 02 Sep 2026
Longboard Pharmaceuticals Inc. (LBPH) Peer Comparison – Compare with Others - Value Research
Sat, 11 Jul 2026
Telesis Bio - DNAY - Stock Price & News - The Motley Fool
Thu, 24 Apr 2025
Lumos Pharma (LUMO) Stock Price, News & Analysis - Stock Titan
Thu, 12 Dec 2024
Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma - The Manila Times
Wed, 06 Nov 2024
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, PIK, INSI on Behalf of Shareholders - globenewswire.com
Wed, 22 May 2024
Sarah Alexander Net Worth (2026) - GuruFocus
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
